SI
APTO

Sofinnova Investments’s Aptose Biosciences, Inc. APTO Stock Holding History

Sofinnova Investments’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,549
Closed -$4.16M – 77
2021
Q1 		$4.16M Sell
1,549
-631
-29% -$1.25M 0.25% 54
2020
Q4 		$4.3M Buy
+2,180
New +$5.12M 0.26% 52

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Sofinnova Investments's APTO Position: Q2 2021 in Review

Sofinnova Investments sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 1,549 shares — an estimated $4.16M sold.

Sofinnova Investments first reported a position in APTO in Q4 2020 and held it in 2 quarters. The position peaked at $4.3M in Q4 2020. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Sofinnova Investments reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Sofinnova Investments sold 1,549 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $4.16M.
  • Sofinnova Investments first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 2 quarters.
  • Sofinnova Investments's Aptose Biosciences, Inc. position peaked at $4.3M in Q4 2020.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Sofinnova Investments's 13F filing for Q2 2021, filed 16 Aug 2021.